| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial
|
Jatoi, A.
|
|
|
28 |
8 |
p. 1957-1963
|
artikel
|
| 2 |
A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer
|
Zhang, A.Y.
|
|
|
28 |
8 |
p. 1903-1909
|
artikel
|
| 3 |
Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
|
Zhao, X.
|
|
|
28 |
8 |
p. 2002-2008
|
artikel
|
| 4 |
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
|
Inhestern, J.
|
|
|
28 |
8 |
p. 1917-1922
|
artikel
|
| 5 |
Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study
|
Spera, G.
|
|
|
28 |
8 |
p. 1836-1841
|
artikel
|
| 6 |
BET inhibitors: a novel epigenetic approach
|
Doroshow, D.B.
|
|
|
28 |
8 |
p. 1776-1787
|
artikel
|
| 7 |
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
|
Bamias, A.
|
|
|
28 |
8 |
p. 1842-1848
|
artikel
|
| 8 |
Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL)
|
Friberg, G.
|
|
|
28 |
8 |
p. 2009-2012
|
artikel
|
| 9 |
Cancer drug costs—the case for a thoughtful discussion of a manageable problem
|
Dhingra, K.
|
|
|
28 |
8 |
p. 1694-1696
|
artikel
|
| 10 |
Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset
|
Eysbouts, Y.K.
|
|
|
28 |
8 |
p. 1856-1861
|
artikel
|
| 11 |
CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 ‘gene desert’, serve as important prognostic biomarkers in colorectal cancer
|
Ozawa, T.
|
|
|
28 |
8 |
p. 1882-1888
|
artikel
|
| 12 |
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
|
Sanmamed, M.F.
|
|
|
28 |
8 |
p. 1988-1995
|
artikel
|
| 13 |
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study
|
Cabel, L.
|
|
|
28 |
8 |
p. 1996-2001
|
artikel
|
| 14 |
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer
|
Mamiya, H.
|
|
|
28 |
8 |
p. 1825-1831
|
artikel
|
| 15 |
64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer
|
Sasada, S.
|
|
|
28 |
8 |
p. 2028-2029
|
artikel
|
| 16 |
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|
Curigliano, G
|
|
|
28 |
8 |
p. 1700-1712
|
artikel
|
| 17 |
Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab
|
Curioni-Fontecedro, A.
|
|
|
28 |
8 |
p. 2040-2041
|
artikel
|
| 18 |
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
|
Germa, C.
|
|
|
28 |
8 |
p. 2021-2024
|
artikel
|
| 19 |
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
|
Earl, H.M.
|
|
|
28 |
8 |
p. 1817-1824
|
artikel
|
| 20 |
Does chemoselection open the door for immunotherapy?
|
Jacobs, M.T.
|
|
|
28 |
8 |
p. 1697-1699
|
artikel
|
| 21 |
Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund
|
Aggarwal, A.
|
|
|
28 |
8 |
p. 1738-1750
|
artikel
|
| 22 |
Drug-induced liver injury in Oncology
|
Ricart, A.D.
|
|
|
28 |
8 |
p. 2013-2020
|
artikel
|
| 23 |
Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer
|
Aoyama, T.
|
|
|
28 |
8 |
p. 1876-1881
|
artikel
|
| 24 |
Editorial board
|
|
|
|
28 |
8 |
p. ii-iii
|
artikel
|
| 25 |
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial
|
Christopoulos, P.
|
|
|
28 |
8 |
p. 1898-1902
|
artikel
|
| 26 |
FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor
|
Wein, L.
|
|
|
28 |
8 |
p. 2025-2027
|
artikel
|
| 27 |
First-onset mental disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study
|
Zhu, J.
|
|
|
28 |
8 |
p. 1964-1969
|
artikel
|
| 28 |
Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR Continuous Update Project
|
Vieira, A.R.
|
|
|
28 |
8 |
p. 1788-1802
|
artikel
|
| 29 |
Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer
|
Martinez Vila, C.
|
|
|
28 |
8 |
p. 2027-2028
|
artikel
|
| 30 |
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
|
Möbus, V.
|
|
|
28 |
8 |
p. 1803-1810
|
artikel
|
| 31 |
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial
|
Leonard, R.C.F.
|
|
|
28 |
8 |
p. 1811-1816
|
artikel
|
| 32 |
Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle?
|
Del Mastro, L.
|
|
|
28 |
8 |
p. 1683-1685
|
artikel
|
| 33 |
Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature
|
Chauhan, A.
|
|
|
28 |
8 |
p. 2034-2038
|
artikel
|
| 34 |
Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial
|
Dhillon, H.M.
|
|
|
28 |
8 |
p. 1889-1897
|
artikel
|
| 35 |
Is complete response the answer?
|
Pusztai, L.
|
|
|
28 |
8 |
p. 1681-1683
|
artikel
|
| 36 |
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
|
Ali, H.R.
|
|
|
28 |
8 |
p. 1832-1835
|
artikel
|
| 37 |
New agents on the horizon in gastric cancer
|
Lordick, F.
|
|
|
28 |
8 |
p. 1767-1775
|
artikel
|
| 38 |
No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
|
Sunakawa, Y.
|
|
|
28 |
8 |
p. 2030-2031
|
artikel
|
| 39 |
Pattern recognition receptors: immune targets to enhance cancer immunotherapy
|
Shekarian, T.
|
|
|
28 |
8 |
p. 1756-1766
|
artikel
|
| 40 |
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from ‘castration-resistant’ prostate cancer
|
Pezaro, C.J.
|
|
|
28 |
8 |
p. 1692-1694
|
artikel
|
| 41 |
Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database
|
Salas, S.
|
|
|
28 |
8 |
p. 1779-1787
|
artikel
|
| 42 |
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
|
Boeckx, N.
|
|
|
28 |
8 |
p. 1862-1868
|
artikel
|
| 43 |
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials †
|
Arnold, D.
|
|
|
28 |
8 |
p. 1713-1729
|
artikel
|
| 44 |
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma
|
Strati, A.
|
|
|
28 |
8 |
p. 1923-1933
|
artikel
|
| 45 |
Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies
|
Rohr, U.-P.
|
|
|
28 |
8 |
p. 1869-1875
|
artikel
|
| 46 |
QoL is a cool tool
|
Procaccio, L.
|
|
|
28 |
8 |
p. 2032-2033
|
artikel
|
| 47 |
Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy
|
Roncolato, F.T.
|
|
|
28 |
8 |
p. 1849-1855
|
artikel
|
| 48 |
Refining prognosis in early-stage colorectal cancer: one or multiple genes at a time?
|
Willis, J.A.
|
|
|
28 |
8 |
p. 1686-1688
|
artikel
|
| 49 |
Reply to the letter to the editor ‘Addressing the quality of the ESMO-MCBS’ by Del Paggio
|
Cherny, N.I.
|
|
|
28 |
8 |
p. 2031-2032
|
artikel
|
| 50 |
Reply to the letter to the editor ‘Specific QOL scales that reflect toxicity-induced impairment are needed in RCTs’
|
Schuurhuizen, C.S.E.W.
|
|
|
28 |
8 |
p. 2033-2034
|
artikel
|
| 51 |
ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia
|
Currow, D.
|
|
|
28 |
8 |
p. 1949-1956
|
artikel
|
| 52 |
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)
|
De Giorgi, U.
|
|
|
28 |
8 |
p. 1910-1916
|
artikel
|
| 53 |
Statistical controversies in cancer research: using standardized effect size graphs to enhance interpretability of cancer-related clinical trials with patient-reported outcomes
|
Bell, M.L.
|
|
|
28 |
8 |
p. 1730-1733
|
artikel
|
| 54 |
Statistical controversies in clinical research: data access and sharing—can we be more transparent about clinical research? Let’s do what’s right for patients
|
Rockhold, F.W.
|
|
|
28 |
8 |
p. 1734-1737
|
artikel
|
| 55 |
Surgery for patients with ‘lower grade’ glioma: putting assumptions, beliefs and convictions into perspective
|
Weller, M.
|
|
|
28 |
8 |
p. 1696-1697
|
artikel
|
| 56 |
Surgical resection versus watchful waiting in low-grade gliomas
|
Jakola, A.S.
|
|
|
28 |
8 |
p. 1942-1948
|
artikel
|
| 57 |
Table of Contents
|
|
|
|
28 |
8 |
p. iv-viii
|
artikel
|
| 58 |
The future of UK healthcare: problems and potential solutions to a system in crisis
|
Montgomery, H.E.
|
|
|
28 |
8 |
p. 1751-1755
|
artikel
|
| 59 |
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
|
Foy, J.-P.
|
|
|
28 |
8 |
p. 1934-1941
|
artikel
|
| 60 |
The influence of socioeconomic status and ethnicity on adjuvant systemic treatment guideline adherence for early-stage breast cancer in the Netherlands
|
Kuijer, A.
|
|
|
28 |
8 |
p. 1970-1978
|
artikel
|
| 61 |
The potential use of lncRNAs found in the 8q24 region as biomarkers for colon cancer
|
White, N.M.
|
|
|
28 |
8 |
p. 1688-1689
|
artikel
|
| 62 |
TRAC(ERx)-ing lung cancer evolution
|
Devarakonda, S.
|
|
|
28 |
8 |
p. 1690-1692
|
artikel
|
| 63 |
Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment
|
Yanagihara, T.
|
|
|
28 |
8 |
p. 2038-2039
|
artikel
|
| 64 |
Whose side are you on?
|
Taieb, J.
|
|
|
28 |
8 |
p. 1685-1686
|
artikel
|
Tijdschrift beschrijving